Medical Writing for Regulatory Dossiers

The Common Technical Document is the universal language of drug registration. Adopted by the ICH and implemented across the US, EU, Japan, and dozens of other markets, the CTD format has been the global standard for marketing authorization applications since its rollout in the early 2000s. It organizes the entire body of evidence for a pharmaceutical product into five modules, and while all five are required, some carry disproportionate weight in determining whether your submission advances or stalls.

Medical writers working on regulatory dossiers are frequently the people who determine whether a submission succeeds or fails at the review stage. Not because reviewers are grading prose, but because clarity, completeness, and logical consistency in the written sections directly influence how quickly and favorably reviewers interpret data. This blog examines the CTD modules that require the most strategic attention and the writing decisions that most often create problems.

Brief Orientation of CTD Architecture

The CTD is organized around five modules. Module 1 contains region-specific administrative and prescribing information and is the only module not harmonized across jurisdictions. Modules 2 through 5 are internationally standardized and form the scientific core of every submission.

Module 2 contains seven sections of summaries and overviews that bridge the detailed data in Modules 3, 4, and 5. Module 3 is the quality module covering chemistry, manufacturing, and controls (CMC). Module 4 contains nonclinical study reports. Module 5 contains clinical study reports. The relationship between Module 2 and Modules 3 through 5 is critical: the summaries in Module 2 must accurately reflect and interpret the data in the later modules. Inconsistencies between them are among the most common reasons for major deficiency notices.

Module 2: Where Medical Writing Is Most Consequential

Medical writers are most heavily involved in Module 2, particularly the Clinical Overview (Section 2.5) and Clinical Summary (Section 2.7). These two documents serve different purposes and must never be confused.

Section 2.5 – The Clinical Overview

The Clinical Overview is a short, critically evaluative document, typically no more than 30 pages, that presents an integrated benefit-risk assessment. It is not a data dump. Reviewers expect authors to take a position, explain the relevance of findings, acknowledge limitations, and make a coherent argument about why the available data supports the proposed indication.

The most common failure in the Clinical Overview is neutrality masquerading as objectivity. Writers who summarize every study without interpretation, who refuse to acknowledge the limitations of subgroup analyses, or who present post hoc outcomes as primary results undermine the document’s purpose. Regulators do not reward vagueness. A Clinical Overview that reads like a literature review rather than a regulatory argument is a document that will generate questions.

Section 2.7 – The Clinical Summary

The Clinical Summary is a longer document focused on data summarization and integration. Its structure is specified in the ICH M4E guidelines and covers clinical pharmacology, clinical efficacy, and clinical safety in distinct subsections. It must include tabulated summaries, and the data presented must be verifiable against the clinical study reports in Module 5. Discrepancies between summary tables and source data are a recurring and serious issue.

Module 3: The Most Technically Demanding Module

Module 3 is widely regarded as the most technically challenging module in a CTD submission. It contains all CMC information: drug substance characterization, manufacturing process description, validation data, impurity profiles, excipients, product development rationale, specifications, and stability data. This module is reviewed by chemists and pharmaceutical scientists, not clinicians, and the level of technical precision required is absolute.

Key areas where Module 3 submissions frequently fail include incomplete process validation data, inadequate control strategy narratives, specifications that are not scientifically justified, and stability data that does not support the proposed shelf life under real-time and accelerated conditions. For biological products, characterization of higher-order structure, glycosylation, and bioactivity must be particularly comprehensive.

The Quality Overall Summary (QOS) in Module 2.3 is the written bridge to Module 3. It must not introduce new information that is not already documented in Module 3, and it must highlight the critical quality attributes and their justification in enough detail to give the reviewer a confident orientation before diving into the full technical package.

Module 5: The Clinical Study Reports

Module 5 contains the individual clinical study reports (CSRs) that document each trial in the development program. The structure and content of CSRs follow ICH E3, and the expectations are detailed. A CSR must be a standalone, self-contained document that allows a reviewer to independently evaluate trial quality, methodology, results, and conclusions without referring to published papers or investigator brochures.

Common deficiencies in Module 5 include protocol deviations that are documented but not analyzed for their impact on key endpoints, patient disposition tables that are inconsistent across studies, adverse event narratives that omit clinically relevant detail, and statistical appendices that do not match the analysis sets described in the statistical analysis plan.

Module 1: The Regional Wildcard

Module 1 is region-specific, which means it must be prepared separately for each target jurisdiction. For the EU, Module 1 follows the eCTD specification version 3.0.4, updated in April 2021, and includes the application form, SmPC, patient information leaflet, and labeling. For the US, Module 1 contains the cover letter, form FDA 356h, patent certifications, and field copy certification.

Writers working on Module 1 need to ensure that the proposed label is consistent with the data summaries in Module 2. A product label that claims more than the evidence supports, or that uses language that does not match the registered indication in the target market, will generate questions that delay the review clock.

Cross-Module Consistency

Regulatory agencies have become increasingly systematic about checking consistency across modules. If the Clinical Overview in Module 2.5 cites a 30% relative risk reduction but the clinical study report in Module 5 shows 28%, the discrepancy must be explained. If the safety narrative in Module 2.7.4 omits an adverse event that appears in the integrated summary of safety in Module 5, the reviewer will find it. Cross-module consistency checks should be a formal step in the review process before submission, conducted by someone who has not written the documents.

Practical Guidance for Medical Writers

Write the Clinical Overview as a regulatory argument, not a scientific review. Take positions. Acknowledge limitations. Justify the benefit-risk conclusion.
Do not write the QOS as a repetition of Module 3 section headings. Use it to emphasize the critical quality attributes and the control strategy logic.
Establish a formal cross-referencing protocol. Every claim in Module 2 that cites specific data should have a traceable cross-reference to the source document in Modules 3, 4, or 5.
Run a consistency check across all Module 2 summaries before finalizing the dossier. Patient numbers, efficacy estimates, and safety frequencies must be identical across sections.
For Module 5 CSRs, follow ICH E3 literally. Reviewers use the guideline as a checklist. Missing sections generate questions even when the data is available elsewhere.

Conclusion

The CTD is not a filing format. It is a structured evidentiary presentation. The quality of medical writing in Modules 2 and 3 often determines not the outcome of the application, but the speed and smoothness of the review. Given that review delays cost real money at every stage, investing in rigorous, well-structured medical writing is one of the highest-return activities in the regulatory process.